Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients.
about
Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented PerspectiveAntipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerabilityAn evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineDevelopment of a Web-Based Clinical Decision Support System for Drug Prescription: Non-Interventional Naturalistic Description of the Antipsychotic Prescription Patterns in 4345 Outpatients and Future ApplicationsMetabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyDrug treatment patterns in bipolar disorder: analysis of long-term self-reported data.Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, CanadaAntipsychotic polypharmacy in a regional health service: a population-based study.Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapyA retrospective study of antipsychotic drug switching in a pediatric population.Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviorReducing psychotropic pharmacotherapy in patients with severe mental illness: a cluster-randomized controlled intervention study.Safety and tolerability of antipsychotic polypharmacy.Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders.Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year ComparisonDifferential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Evidence review and clinical guidance for the use of ziprasidone in Canada.Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceEfficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study.Ecological Assessment of Clinicians' Antipsychotic Prescription Habits in Psychiatric Inpatients: A Novel Web- and Mobile Phone-Based Prototype for a Dynamic Clinical Decision Support SystemRe-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review.Treatment of clozapine-associated weight gain: a systematic review.Antipsychotic switching in schizoaffective disorder: A systematic review.Current psychotropic medication prescribing patterns in late-life bipolar disorder.Academic detailing among psychiatrists - feasibility and acceptability.Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy.Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy.Psychotropic drug-regimen changes between community treatment orders.Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs.Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings.Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats.Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice.Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
P2860
Q26786284-C8AD2D59-8FCE-4F6C-BDF3-37F92AD87A9FQ28287983-9A72E635-1A9E-4F9D-A47F-E5D45FA2E368Q28543222-20C9DF29-7892-48C5-BF73-75D765783C42Q28552825-9F6765F9-6A6A-4C89-A9E3-8686FC6344D4Q30459096-D29ECC7B-9962-47EC-A979-175BB97F435BQ30485065-E8882B25-B758-4BD0-AF72-D1852B090AE8Q30878126-F174E5AB-CFAB-451C-ACA2-E0D7FC97F8F6Q34139645-7784311E-1BA4-4038-930E-08D224C0BA35Q34269517-635F12FA-6241-4E5A-8296-0B4F3B8A370DQ34686544-21363FD5-F23B-4BAF-B0C7-F0B05FA4AA37Q35011070-37CC3DCF-3C5D-4921-9571-1D1973376E78Q35175610-7F5E0BD2-9C08-4782-8B97-FD0078756206Q35906535-11F4E1F9-9CFB-4E26-91C8-3801B6AC719BQ36062421-46B30E2E-4A3B-4348-88CE-8F9E153CECC7Q36081021-C85347B2-CA54-452A-A439-BD786024D69FQ36325431-579CC9CE-6B1D-4427-BB3C-B08D0A202B05Q36383322-88FB87BA-4A3D-401E-AEAF-CE1AB39D92EEQ36588607-B4E5B27E-9C01-4289-8718-F8C4D427BC6FQ36987106-9CF6F013-4254-4462-AE1E-62EAA09E5200Q37029622-977222CB-6261-4055-9854-451414A8D10CQ37579469-E996FD96-0F5A-4BFD-B99F-8487F3BD7500Q37634839-5A71BCC9-6403-4701-B63D-E9FD6059E177Q38232547-C622A121-1694-4C37-8314-95CD16E20D79Q38334922-F2E2D6B6-F0FE-409D-9184-5BA71F1296A6Q38370545-CD3B1758-F852-41DF-9E20-931FC9F00DC9Q38788092-3EB7EBBD-0D17-4A6E-A9D9-FCD7EDB16C23Q39010717-8677B4D6-1703-4828-95BA-DD14C1D37B47Q41682303-C73C441C-BA5C-4211-ACD5-ED57C68174B6Q42180852-3EC74CB6-9E6D-4095-8124-80AE7A0FF823Q42707831-FA36D64A-17AC-4EA6-A0C4-9935DE6E298CQ42860052-2FF187A1-DCC0-4DC9-A54D-5BF4A9EB34C9Q44804806-B9F4FAC4-A9B9-4655-9EBD-BF738DA06972Q47368888-DA0324D2-E27E-4D0E-B9C4-2AAD3C35D35EQ47571460-8481726D-6EC9-4F5B-B37C-FD393A1985E5Q47762878-E9E6E962-A9CD-4EE8-8004-0CEA30E7144CQ47865590-3FC9BEB5-A714-439C-8D75-49B040093E9AQ48484923-C8F3A65A-46A9-4EC9-A910-A50D0F6C3A45Q49456987-118FA0AC-A623-4B0A-B458-549805B04C07Q50134375-67F8EECD-F5F0-4403-AA3E-AA7BDCC1BAD7Q50709810-036AB4C8-42F5-4A5D-B6CF-69CB5A9DD3FB
P2860
Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistent antipsychotic polyp ...... s in 435 Canadian outpatients.
@en
Persistent antipsychotic polyp ...... s in 435 Canadian outpatients.
@nl
type
label
Persistent antipsychotic polyp ...... s in 435 Canadian outpatients.
@en
Persistent antipsychotic polyp ...... s in 435 Canadian outpatients.
@nl
prefLabel
Persistent antipsychotic polyp ...... s in 435 Canadian outpatients.
@en
Persistent antipsychotic polyp ...... s in 435 Canadian outpatients.
@nl
P2093
P50
P356
P1476
Persistent antipsychotic polyp ...... es in 435 Canadian outpatients
@en
P2093
Allan H Young
Rebecca W Y Ko
Sean A McIsaac
Tony K Y Wu
P304
P356
10.4088/JCP.08M04912GRE
P577
2010-03-09T00:00:00Z